201 related articles for article (PubMed ID: 20978502)
1. Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials.
Al-Batran SE; Güntner M; Pauligk C; Scholz M; Chen R; Beiss B; Stopatschinskaja S; Lerbs W; Harbeck N; Jäger E
Br J Cancer; 2010 Nov; 103(10):1518-23. PubMed ID: 20978502
[TBL] [Abstract][Full Text] [Related]
2. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
[TBL] [Abstract][Full Text] [Related]
3. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial.
Al-Batran SE; Bischoff J; von Minckwitz G; Atmaca A; Kleeberg U; Meuthen I; Morack G; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
Br J Cancer; 2006 Jun; 94(11):1615-20. PubMed ID: 16685267
[TBL] [Abstract][Full Text] [Related]
4. Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center.
Khallaf SM; Roshdy J; Ibrahim A
J Egypt Natl Canc Inst; 2020 Apr; 32(1):20. PubMed ID: 32372114
[TBL] [Abstract][Full Text] [Related]
5. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer.
Chow LW; Yip AY; Lang BH
Am J Clin Oncol; 2007 Apr; 30(2):133-8. PubMed ID: 17414461
[TBL] [Abstract][Full Text] [Related]
7. Pegylated liposomal doxorubicin (Caelyx®) and oral vinorelbine in first-line metastatic breast cancer patients previously treated with anthracyclines.
Livi L; Meattini I; Scotti V; De Luca Cardillo C; Galardi A; Iermano C; Sanchez L; Nori J; Mangoni M; Franzese C; Orzalesi L; Bertocci S; Agresti B; Masoni T; Bianchi S; Cataliotti L; Biti G
J Chemother; 2011 Jun; 23(3):158-62. PubMed ID: 21742585
[TBL] [Abstract][Full Text] [Related]
8. Pegylated liposomal doxorubicin (Duomeisu
Jiang H; Li H; Song G; Di L; Shao B; Yan Y; Liu X; Chen Y; Zhang R; Ran R; Liu Y; Gui X; Wang N; Wang H
Breast Cancer Res Treat; 2023 May; 199(1):67-79. PubMed ID: 36877215
[TBL] [Abstract][Full Text] [Related]
9. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines.
Verma S; Dent S; Chow BJ; Rayson D; Safra T
Cancer Treat Rev; 2008 Aug; 34(5):391-406. PubMed ID: 18358614
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.
Harbeck N; Saupe S; Jäger E; Schmidt M; Kreienberg R; Müller L; Otremba BJ; Waldenmaier D; Dorn J; Warm M; Scholz M; Untch M; de Wit M; Barinoff J; Lück HJ; Harter P; Augustin D; Harnett P; Beckmann MW; Al-Batran SE;
Breast Cancer Res Treat; 2017 Jan; 161(1):63-72. PubMed ID: 27798749
[TBL] [Abstract][Full Text] [Related]
11. Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients.
Fabi A; Ferretti G; Papaldo P; Salesi N; Ciccarese M; Lorusso V; Carlini P; Carpino A; Mottolese M; Cianciulli AM; Giannarelli D; Sperduti I; Felici A; Cognetti F
Cancer Chemother Pharmacol; 2006 May; 57(5):615-23. PubMed ID: 16163541
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Keller AM; Mennel RG; Georgoulias VA; Nabholtz JM; Erazo A; Lluch A; Vogel CL; Kaufmann M; von Minckwitz G; Henderson IC; Mellars L; Alland L; Tendler C
J Clin Oncol; 2004 Oct; 22(19):3893-901. PubMed ID: 15459210
[TBL] [Abstract][Full Text] [Related]
13. Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial.
Fiegl M; Mlineritsch B; Hubalek M; Bartsch R; Pluschnig U; Steger GG
BMC Cancer; 2011 Aug; 11():373. PubMed ID: 21864402
[TBL] [Abstract][Full Text] [Related]
14. Multicenter experience of nonpegylated liposomal doxorubicin use in the management of metastatic breast cancer.
Palmieri C; Misra V; Januszewski A; Yosef H; Ashford R; Keary I; Davidson N
Clin Breast Cancer; 2014 Apr; 14(2):85-93. PubMed ID: 24325950
[TBL] [Abstract][Full Text] [Related]
15. Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines.
Vassilomanolakis M; Koumakis G; Barbounis V; Demiri M; Pateras H; Efremidis AP
Ann Oncol; 2000 Sep; 11(9):1155-60. PubMed ID: 11061611
[TBL] [Abstract][Full Text] [Related]
16. A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer.
Huober J; Fett W; Nusch A; Neise M; Schmidt M; Wischnik A; Gerhardt S; Goehler T; Lück HJ; Rost A
BMC Cancer; 2010 Jan; 10():2. PubMed ID: 20047698
[TBL] [Abstract][Full Text] [Related]
17. A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study.
Vici P; Colucci G; Giotta F; Sergi D; Filippelli G; Perri P; Botti C; Vizza E; Carpino A; Pizzuti L; Latorre A; Giannarelli D; Lopez M; Di Lauro L
J Exp Clin Cancer Res; 2011 Apr; 30(1):39. PubMed ID: 21481280
[TBL] [Abstract][Full Text] [Related]
18. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer.
O'Brien ME
Anticancer Drugs; 2008 Jan; 19(1):1-7. PubMed ID: 18043124
[TBL] [Abstract][Full Text] [Related]
19. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
Vassilomanolakis M; Koumakis G; Demiri M; Missitzis J; Barbounis V; Efremidis AP
Cancer Invest; 2003; 21(4):497-504. PubMed ID: 14533438
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.
Smorenburg CH; de Groot SM; van Leeuwen-Stok AE; Hamaker ME; Wymenga AN; de Graaf H; de Jongh FE; Braun JJ; Los M; Maartense E; van Tinteren H; Nortier JWR; Seynaeve C
Ann Oncol; 2014 Mar; 25(3):599-605. PubMed ID: 24504445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
